Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. [redacted]
Application No: Not yet assigned
Attorney Docket No: PP16021.002 (35784/213736)

Liquid rFGF-2 Formulations CN-RP-HPLC % Main Peak 4°C



Figure 1

Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Gupta
Application No: Not yet assigned
Atty Dkt No: PP16021.002 (35784/213736)

rFGF-2 Liquid Formulations
CN-RP-HPLC
% Main Peak
17°C



Figure 2

Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
Application No: Not yet assigned
Atty Dkt No: PP16021.002 (35784/213736)

rFGF-2 Liquid Formulations CN-RP-HPLC % Main Peak 30°C



Figure 3

Liquid rFGF-2 Formulations
% Main Peak
CN-RP-HPLC
30°C



Figure 4

Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
Application No: Not yet assigned
Atty Dkt No: PP16021.002 (35784/213736)

Lyophilized rFGF-2 Formulations
CN-RP-HPLC
% Main Peak
40°C



Figure 5

All formulations contain:

10 mM sodium citrate
2% glycine
1% sucrose
1 mM EDTA

Title: Stabilized FGF Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
Application No: Not yet assigned
Atty Dkt No: PP16021.002 (35784/213736)

Lyophilized rFGF-2 Formulations
CN-RP-HPLC
% Main Peak
50°C



Figure 6

All formulations contain:

10 mM sodium citrate
2% glycine
1% sucrose
1 mM EDTA

Title: Stabilized Formulations Containing Reducing Agents
Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa
Application No: Not yet assigned
Atty Dkt No: PP16021.002 (35784/213736)

rhFGF2 Stability
30°C
RP-HPLC
% Main Peak



Figure 7